Home Medizin Eine vollständig autonome Einzelzellenplattform zur Echtzeitüberwachung funktioneller Tests

Eine vollständig autonome Einzelzellenplattform zur Echtzeitüberwachung funktioneller Tests

von NFI Redaktion

ARRALYZE®, the life science division of LPKF Laser & Electronics SE, is proud to announce the commercial availability of CellShepherd®. Following a successful beta testing phase in 2023, this groundbreaking platform is now ready to revolutionize cell-based research and development in biomedicine and various areas of the life sciences.

CellShepherd®: Redefining Single-cell Analysis

Developed by ARRALYZE®, CellShepherd® addresses the urgent need for advanced functional cell screening technologies in academic and industrial laboratories. It is distinguished by ARRALYZE’s proprietary nanowell glass arrays, which miniaturize cell-based assays while allowing real-time monitoring at the single-cell level.

This autonomous platform features precise nanoliter dosage in glass wells and supports (co-)cultivation under climate-controlled sterile conditions. Its capabilities extend to real-time imaging through a bright field microscope and three fluorescence channels.

By utilizing advanced AI-driven analyses, CellShepherd® precisely counts and tracks cells, providing essential insights into various parameters. This innovation promises a new era of scientific research characterized by precision, control, and profound insights.

Meeting Market Demands: The ARRALYZE® Vision

CellShepherd® aims to meet the growing demand for technologies that enable the examination of small and large cell populations at the single-cell level and the isolation of target cells. Taking a holistic approach, ARRALYZE® enables customers to uncover individual characteristics of heterogeneous cell populations, gain insights into experiment kinetics, and monitor functionality at various time points.

This approach overcomes challenges such as harsh experimental conditions, limited control of the microenvironment, and difficulties in maintaining cell viability.

Main Features and Advantages

  • Proprietary nanowell glass arrays for precise miniaturization of cell-based tests.
  • Precise dispensing of cell suspensions with excellent viability.
  • Autonomous operation to support (co-)cultivation in a climate-controlled sterile environment.
  • Advanced real-time imaging capabilities, including a bright field microscope and three fluorescence channels.
  • AI-driven analysis for accurate cell counting and tracking.
  • User-friendly interface for easy setup, monitoring, and analysis of experiments.
  • Ability to isolate living cells for downstream processes, increasing versatility and applicability.

About LPKF

LPKF Laser & Electronics SE, the parent company of ARRALYZE, is a leading provider of laser-based solutions for the technology industry. Founded in 1976, the company is headquartered in Germany and operates globally through subsidiaries and representatives. The establishment of ARRALYZE as a standalone business division underscores LPKF’s commitment to innovation and excellence in the biotechnology sector. The shares of LPKF Laser & Electronics SE are traded on the Prime Standard segment of the Deutsche Börse (ISIN 0006450000).


For more information about CellShepherd® and ARRALYZE®, please visit www.arralyze.com or contact us via email at [email protected]

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.